Results 111 to 120 of about 5,494 (193)

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease

Alzheimer’s Research & Therapy
Background With the approval of disease-modifying treatments (DMTs) for early Alzheimer’s disease (AD), there is an increased need for efficient and non-invasive detection methods for cerebral amyloid-β (Aβ) pathology. Current methods, including positron
Matthew D. Howe, Karysa J. Britton, Hannah E. Joyce, William Menard, Sheina Emrani, Zachary J. Kunicki, Melanie A. Faust, Brittany C. Dawson, Meghan C. Riddle, Edward D. Huey, Shorena Janelidze, Oskar Hansson, Stephen P. Salloway   +12 more
doaj   +1 more source

Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab

Alzheimer’s disease (AD) is a neurodegenerative condition that causes cognitive decline, memory loss, and reduced personal autonomy. The pathology of AD involves the aggregation of abnormal brain proteins, specifically beta-amyloid plaques and tau ...
Abdul Raheem, Syed Muhammad Sinaan Ali, Syed Muhammad Iraj Abbas, Taha Basit Ameen, Syeda Naveera Kashif, Kulsoom Babar   +5 more
core   +1 more source

Topography and risk factors of amyloid-related imaging abnormality: real-world data from 168 aducanumab-treated patients at a private clinic in South Korea. [PDF]

Alzheimers Dement (Amst)
Yoon S, Ahn J, Kim S, Kim K, Kim SY, An SK, Na DG, Kim YJ, Kwak K, Seo SW, Na DL.   +10 more
europepmc   +1 more source

Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease. [PDF]

JAMA
Brown CA, Robinson JL, Das SR, McGrew E, Suh E, Van Deerlin VM, Irwin DJ, Nasrallah IM, Mechanic-Hamilton D, Yushkevich PA, Wolk DA, Lee EB.   +11 more
europepmc   +1 more source

Análise da eficácia clínica do fármaco Aducanumab no tratamento da Doença de Alzheimer [PDF]

A Doença de Alzheimer trata-se de um distúrbio neurodegenerativo progressivo, caracterizado pelo acúmulo da proteína β -amiloide no tecido parenquimatoso cerebral, levando a formação de placas amiloides na matriz extracelular entre os neurônios e ...
Turke, Camille Corcione, Estrela, Heder Frank Gianotto, Zumbano, Giulia Matiusso, Camargo, Rafaella Mendes, Chvojka Neto, Vladimir, Morelli, Sofia de Almeida, Akamine, Marcela Yumi Eleuterio, Shimada, Tatiana   +7 more
core   +1 more source

Spectrum of amyloid-related imaging abnormalities associated with aducanumab treatment: a case series report. [PDF]

BMC Neurol
Atri A, Curiale GG, Aisen P, Barakos J, Purcell D, Bracoud L, Haeberlein SB, Grassi C, Hughes R, Smirnakis K.   +9 more
europepmc   +1 more source

Sustaining Drug Discovery Amid the Limits of Alzheimer's Disease Immunotherapies. [PDF]

eNeuro
McDiarmid A.
europepmc   +1 more source

Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease. [PDF]

Acta Neuropathol
Welikovitch LA, Oakley DH, Bennett RE, Serrano-Pozo A, Zhu H, Ruiz-Uribe NE, Zwang TJ, Chibnik LB, Gomez-Isla T, Frosch MP, Marks DS, Salloway S, Bernick C, Greeley D, Latimer CS, Nolan A, Hutchison RM, Rubel CE, Bussiere T, Plowey ED, Keene CD, Hyman BT.   +21 more
europepmc   +1 more source

Anti-amyloid nanobody-Fc fusion protein drives potent amyloid clearance through microglial recruitment. [PDF]

Alzheimers Dement (N Y)
Ding Z, Gibson KA, Nascari DG, Tallant LE, Bouchal SM, Dickson DW, Fryer JD.   +6 more
europepmc   +1 more source

Anti-amyloid antibody equilibrium binding to Aβ aggregates from human Alzheimer's disease brain. [PDF]

Alzheimers Dement
Bjørnholm KD, Butler PM, Francis AE, Varma C, Spooner ET, Grenon MB, Xu YR, Tao Y, Meunier AL, Anderson AK, Hennessey EL, Miller MB, Selkoe DJ, Lemere CA, Stern AM.   +14 more
europepmc   +1 more source